Brown Brothers Harriman & Co. Sells 27,144 Shares of Zoetis Inc. (NYSE:ZTS)

Brown Brothers Harriman & Co. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,042,367 shares of the company’s stock after selling 27,144 shares during the quarter. Zoetis comprises about 2.7% of Brown Brothers Harriman & Co.’s portfolio, making the stock its 14th biggest position. Brown Brothers Harriman & Co. owned 0.45% of Zoetis worth $354,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. International Assets Investment Management LLC raised its position in shares of Zoetis by 40.7% during the fourth quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock worth $479,000 after acquiring an additional 703 shares during the last quarter. Aveo Capital Partners LLC bought a new stake in Zoetis during the 4th quarter worth about $225,000. Gryphon Financial Partners LLC lifted its position in Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after purchasing an additional 322 shares during the period. Jump Financial LLC bought a new position in shares of Zoetis in the 4th quarter valued at about $339,000. Finally, Foundations Investment Advisors LLC raised its stake in shares of Zoetis by 12.8% during the fourth quarter. Foundations Investment Advisors LLC now owns 1,564 shares of the company’s stock worth $296,000 after buying an additional 177 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price objective on shares of Zoetis in a research note on Tuesday, August 27th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Trading Up 0.2 %

NYSE:ZTS opened at $191.09 on Monday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business’s 50-day simple moving average is $182.85 and its 200-day simple moving average is $174.14. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market capitalization of $86.57 billion, a PE ratio of 36.82, a price-to-earnings-growth ratio of 2.92 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the firm posted $1.41 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. Sell-side analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.